» Articles » PMID: 35562364

Which Cell Death Modality Wins the Contest for Photodynamic Therapy of Cancer?

Overview
Journal Cell Death Dis
Date 2022 May 13
PMID 35562364
Authors
Affiliations
Soon will be listed here.
Abstract

Photodynamic therapy (PDT) was discovered more than 100 years ago. Since then, many protocols and agents for PDT have been proposed for the treatment of several types of cancer. Traditionally, cell death induced by PDT was categorized into three types: apoptosis, cell death associated with autophagy, and necrosis. However, with the discovery of several other regulated cell death modalities in recent years, it has become clear that this is a rather simple understanding of the mechanisms of action of PDT. New observations revealed that cancer cells exposed to PDT can pass through various non-conventional cell death pathways, such as paraptosis, parthanatos, mitotic catastrophe, pyroptosis, necroptosis, and ferroptosis. Nowadays, immunogenic cell death (ICD) has become one of the most promising ways to eradicate tumor cells by activation of the T-cell adaptive immune response and induction of long-term immunological memory. ICD can be triggered by many anti-cancer treatment methods, including PDT. In this review, we critically discuss recent findings on the non-conventional cell death mechanisms triggered by PDT. Next, we emphasize the role and contribution of ICD in these PDT-induced non-conventional cell death modalities. Finally, we discuss the obstacles and propose several areas of research that will help to overcome these challenges and lead to the development of highly effective anti-cancer therapy based on PDT.

Citing Articles

Targeting ocular malignancies using a novel light-activated virus-like drug conjugate.

Ma S, Huis Int Veld R, Pinos E, Ossendorp F, Jager M Adv Ophthalmol Pract Res. 2025; 5(1):49-57.

PMID: 39911685 PMC: 11795595. DOI: 10.1016/j.aopr.2024.12.001.


Cancer stem cell populations are resistant to 5-aminolevulinic acid-photodynamic therapy (5-ALA-PDT).

Rice C, Chelakkot V, Conohan N, Hirasawa K Sci Rep. 2025; 15(1):4367.

PMID: 39910203 PMC: 11799205. DOI: 10.1038/s41598-025-88173-3.


Applications and enhancement strategies of ROS-based non-invasive therapies in cancer treatment.

Guo Q, Tang Y, Wang S, Xia X Redox Biol. 2025; 80:103515.

PMID: 39904189 PMC: 11847112. DOI: 10.1016/j.redox.2025.103515.


Extracellular matrix re-normalization to improve cold tumor penetration by oncolytic viruses.

Soko G, Kosgei B, Meena S, Ng Y, Liang H, Zhang B Front Immunol. 2025; 15():1535647.

PMID: 39845957 PMC: 11751056. DOI: 10.3389/fimmu.2024.1535647.


Self-Assembly Nanomedicine Initiating Cancer-Immunity Cycle with Cascade Reactions for Boosted Immunotherapy.

Guo Y, Liu B, Yin L, Zhou Y, Wu Y, Liu H Chem Eng J. 2025; 503.

PMID: 39829948 PMC: 11737515. DOI: 10.1016/j.cej.2024.158143.


References
1.
Dougherty T, Gomer C, Henderson B, Jori G, Kessel D, Korbelik M . Photodynamic therapy. J Natl Cancer Inst. 1998; 90(12):889-905. PMC: 4592754. DOI: 10.1093/jnci/90.12.889. View

2.
Plaetzer K, Krammer B, Berlanda J, Berr F, Kiesslich T . Photophysics and photochemistry of photodynamic therapy: fundamental aspects. Lasers Med Sci. 2008; 24(2):259-68. DOI: 10.1007/s10103-008-0539-1. View

3.
Agostinis P, Berg K, Cengel K, Foster T, Girotti A, Gollnick S . Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011; 61(4):250-81. PMC: 3209659. DOI: 10.3322/caac.20114. View

4.
Yoo J, Ha K . New insights into the mechanisms for photodynamic therapy-induced cancer cell death. Int Rev Cell Mol Biol. 2012; 295:139-74. DOI: 10.1016/B978-0-12-394306-4.00010-1. View

5.
Castano A, Demidova T, Hamblin M . Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization. Photodiagnosis Photodyn Ther. 2014; 1(4):279-93. PMC: 4108220. DOI: 10.1016/S1572-1000(05)00007-4. View